Market Research Logo

Insulin Market in the US and Europe 2016-2020

About Insulin

Beta cells of the pancreas produce insulin, a hormone that regulates blood glucose levels, by stimulating cells to absorb glucose from the blood. In the cells, glucose is converted into energy, which is used by tissues and muscles to perform their physiological functions. This process is restricted in people with diabetes, resulting in the accumulation of glucose in the blood. This condition is known as hyperglycemia; it damages body tissues over a period, leading to life-threatening health complications such as diabetic retinopathy and diabetic nephropathy. In type 1 diabetes or gestational diabetes, the immune system attacks the pancreatic cells, resulting in little or no insulin production. In type 2 diabetes, the body does not produce sufficient insulin to regulate blood glucose levels. In both type 1 and type 2 diabetes, the individual requires daily doses of insulin along with other medications, depending on the condition. Different types of insulin products, such as human insulin and insulin analogs, are available for insulin replacement therapy.

Technavio’s analysts forecast the insulin market in the US and Europe to grow at a CAGR of 6.17% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the insulin market in the US and Europe for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the branded drugs during the forecast period.

The market is divided into the following segments based on geography:

  • US
  • Europe
Technavio's report, Insulin Market in the US and Europe 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Sanofi
  • Novo Nordisk
  • Eli Lilly
Other prominent vendors
  • Adocia
  • Biocon
  • Biodel
  • Biogenomics
  • Boehringer Ingelheim
  • Dance Biopharm
  • Diasome Pharmaceuticals
  • Exsulin
  • Generex
  • Lexicon Pharmaceuticals
  • Ligand Pharmaceuticals
  • MannKind
  • Macrogenics
  • Merck
  • Melior Pharmaceuticals
  • Metabolic Solutions Development Company
  • NGM Biopharmaceuticals
  • NuSirt Biopharma
  • Oramed Pharmceuticals
  • PhaseBio Pharmaceuticals
  • Pfizer
  • Thermalin Diabetes
  • Tolerion
  • VeroScience
  • vTv Therapeutics
  • Wockhardt
  • XOMA
Market driver
  • Advances in insulin delivery technology
  • For a full, detailed list, view our report
Market challenge
  • Complexity of insulin production
  • For a full, detailed list, view our report
Market trend
  • Increasing price of insulin drugs
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

  • Press Release

    Technavio Announces the Publication of its Research Report – Insulin Market in the US and Europe 2016-2020

    Technavio recognizes the following companies as the key players in the Insulin Market in the US and Europe: Sanofi, Novo Nordisk, and Eli Lilly.

    Other Prominent Vendors in the market are: Adocia, Biocon, Biodel, Biogenomics, Boehringer Ingelheim, Dance Biopharm, Diasome Pharmaceuticals, Exsulin, Generex, Lexicon Pharmaceuticals, Ligand, MannKind, Macrogenics, Merck, Melior Pharmaceuticals, Metabolic Solutions Development Company, NGM Biopharmaceuticals, NuSirt Biopharma, Oramed Pharmaceuticals, PhaseBio Pharmaceuticals, Pfizer, Thermalin Diabetes, Tolerion, VeroScience, vTV Therapeutics, Wockhardt, and XOMA.

    Commenting on the report, an analyst from Technavio’s team said: “A trend to note is the rising prices of insulin drugs. Apart from safety and efficacy, the cost of therapy plays a major role in deciding the number of consumers. The cost-effectiveness of a treatment needs to be analyzed while prescribing a therapy. However, due to the lack of alternative therapies, drugs like insulin are the standard treatment options despite their high cost. The insulin market in the US and Europe is expected to grow based on the rising prices of insulin analogs.”

    According to the report, a key growth driver is the advances in insulin delivery technology. The development of innovative insulin products and advances in insulin delivery technology have increased the life expectancy of individuals with diabetes. Automated injection devices such as insulin pumps and pens offers a safe and easy drug delivery option, increasing their demand in the market. For instance, NovoPen and FlexTouch by Novo Nordisk are the latest developments in durable insulin delivery devices.

    Further, the report states that one challenge that could have an adverse impact on market growth is the complexity of the insulin production process.



    Companies Mentioned

    Sanofi, Novo Nordisk, Eli Lilly, Adocia, Biocon, Biodel, Biogenomics, Boehringer Ingelheim, Dance Biopharm, Diasome Pharmaceuticals, Exsulin, Generex, Lexicon Pharmaceuticals, Ligand, MannKind, Macrogenics, Merck, Melior Pharmaceuticals, Metabolic Solutions Development Company, NGM Biopharmaceuticals, NuSirt Biopharma, Oramed Pharmaceuticals, PhaseBio Pharmaceuticals, Pfizer, Thermalin Diabetes, Tolerion, VeroScience, vTV Therapeutics, Wockhardt, XOMA.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Assumptions:
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
    • Key buying criteria
      • Table Key buying criteria for insulin
  • Major branded drug profiles
    • Actrapid
    • Apidra
    • Humalog
    • Insuman
    • Lantus
    • Levemir
    • NovoMix
    • NovoRapid
    • Toujeo
    • Tresiba
  • Insulin: An overview
    • History of insulin
      • Table History of insulin development
    • Epidemiology
      • Table Incidence of diabetes among ethnic groups in US 2014
      • Table Diagnosed and undiagnosed diabetes in US by gender 2012
      • Table Diagnosed and undiagnosed diabetes in people aged 20 years or older in US 2012
      • Table Diabetes in people aged 20-79 years in Europe 2013 and 2035
      • Table Proportion of diabetes in top countries of Europe 2013 (millions)
      • Table Diabetes in Europe among people aged 20-79 years by gender 2014
    • Reimbursement scenario
    • Patent scenario for approved products
      • Table Approved product portfolio
  • Pipeline portfolio
    • Table Pipeline portfolio: Insulin market in US and Europe
    • Xultophy (NN9068)
    • Faster-acting insulin aspart (NN1218)
    • SAR342434
    • LY2605541
    • MK-1293
    • Oral-Lyn
      • Table Share of pipeline products in insulin market in US and Europe by stage ofdevelopment 2015
      • Table Pipeline share of top companies in insulin market in US and Europe
  • Oral insulin therapies
    • Upcoming vendors for oral insulin therapies
    • Oramed Pharmaceuticals
      • Table Oramed Pharmaceuticals: Pipeline products
    • Generex Biotechnology
  • Market landscape
    • Global insulin market
      • Table Global insulin market 2015-2020 ($ billions)
      • Table Market share of global insulin drugs in global pharmaceutical market 2015
    • Insulin market in US and Europe
    • Market size and forecast
      • Table Global insulin market in the US and Europe 2015-2020 ($ billions)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by drug class
    • Table Segmentation of insulin market in US and Europe by drug class
    • Fast-acting insulin
    • Intermediate-acting insulin
    • Long-acting insulin
      • Table Market share of insulin in US and Europe by drug class
      • Table Marketed insulin formulations
  • Market segmentation by application
    • Type 1 diabetes
    • Type 2 diabetes
      • Table Insulin market in US and Europe by application 2015
  • Market segmentation by insulin delivery technologies
    • Table Insulin delivery technologies
    • Injectable insulin
    • Oral insulin
    • Inhaled insulin
    • Other emerging insulin delivery technologies
    • Insulin pumps
      • Table Insulin pumps market in US 2015-2020 ($ millions)
      • Table Insulin pumps market in Europe 2015-2020 ($ millions)
  • Geographical segmentation
    • Table Geographical segmentation of insulin market in US and Europe 2015
    • Insulin market in US
      • Table Insulin market in US 2015-2020 ($ billions)
      • Table Market share of insulin in US by drug class 2015
    • Insulin market in Europe
      • Table Insulin market in Europe 2015-2020 ($ billions)
      • Table Market share of insulin in Europe by drug class 2015
  • Market drivers
    • Advances in insulin delivery technology
    • Unmet medical needs
      • Table Unmet medical needs in insulin market in US and Europe
    • Increase in prevalence of diabetes and obesity
    • Increase in awareness of diabetes
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Complexity of insulin production
    • Poor storage condition and distribution policies
    • Stringent regulatory environment
    • Inconvenient ROA
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Increase in R&D for novel mechanisms
    • Increase in academia-industry collaborations for drug development
    • Increasing price of insulin drugs
    • Intense competition among present and upcoming vendors
  • Vendor landscape
    • Competitive scenario
    • Market share analysis 2015
      • Table Market share analysis 2015
      • Table Revenue share of major companies for insulin market in US and Europe 2015
      • Table Revenues from the sales of top five products in insulin market in US and Europe2013-2015 ($ billions)
    • Sanofi
      • Table Sanofi: YoY revenue and growth rate of Lantus 2013-2015 ($ billions)
      • Table Sanofi: Geographical segmentation of Lantus 2015
      • Table Sanofi: YoY revenue and growth rate of Apidra 2013-2015 ($ millions)
      • Table Sanofi: Geographical segmentation of Apidra 2015
      • Table Sanofi: Geographical segmentation of Toujeo 2015
      • Table Sanofi: YoY revenue and growth rate of Insuman 2013-2015 ($ millions)
      • Table Sanofi: Geographical segmentation of Insuman 2015
      • Table Sanofi: Key takeaways
    • Novo Nordisk
      • Table Novo Nordisk: YoY growth and revenue of NovoLog/NovoRapid 2013-2015 ($billions)
      • Table Novo Nordisk: Geographical segmentation of revenues of NovoLog 2015
      • Table Novo Nordisk: YoY growth and revenue of NovoMix/NovoLog mix 2013-2015 ($billions)
      • Table Novo Nordisk: Geographical segmentation of revenues of NovoMix 2015
      • Table Novo Nordisk: YoY revenue and sales growth of Levemir 2013-2015 ($ billions)
      • Table Geographical segmentation of Levemir 2015
      • Table Novo Nordisk: YoY revenue and growth rate of human insulins 2013-2015 ($billions)
      • Table Geographical segmentation of human insulins 2015
      • Table Novo Nordisk: Key takeaways
    • Eli Lilly
      • Table Eli Lilly: YoY revenue and growth rate of Humalog 2013-2015 ($ billions)
      • Table Eli Lilly: Geographical segmentation of Humalog 2015
      • Table Eli Lilly: YoY revenue and growth rate of Humulin 2013-2015 ($ billions)
      • Table Eli Lilly: Geographical segmentation of Humalog 2015
      • Table Eli Lilly: Key takeaways
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report